PhRMA Floats Study To USTR, Congress Backing Six-Year TPP Window

摘要

The Pharmaceutical Research and Manufacturers of America (PhRMA) has presented a new study to the Office of the U.S. Trade Representative and Congress that backs up its recommendations that the "access window" envisioned in the U.S. drug patent proposal in the Trans-Pacific Partnership talks should be six years long. The U.S. proposal defines the access window as the period between a company's application for initial marketing approval in a major market such as the United States and the subsequent application in another TPP country. Companies that make the second filing within the yet unspecified access window would qualify for stronger protections in the areas of patent term extensions, patent linkage and data exclusivity.